Alkylation of the tumor suppressor PTEN activates Akt and β-catenin signaling: A mechanism linking inflammation and oxidative stress with cancer

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Covey, Tracy M ^a,b   Edes, Kornelia ^a   Coombs, Gary S ^a,b   Virshup, David M ^a,b   Fitzpatrick, Frank A ^a,c  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c KANSAS CITY UNIVERSITY OF MEDICINE AND BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 4 HYDROXYNONENAL; ACROLEIN; ALDEHYDE; BETA CATENIN; DELTA12 PROSTAGLANDIN J2; KETONE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN A2; PROTEIN KINASE B; PTEN PROTEIN, HUMAN;

ALKYLATION; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; COVALENT BOND; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; METABOLISM; NEOPLASM;

ALKYLATION; BETA CATENIN; ENZYME ACTIVATION; HUMANS; INFLAMMATION; NEOPLASMS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 78149448121     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013545     Document Type: Article

References (59)

1. Peek RM, Jr., Mohla S, DuBois RN (2005) Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting. Cancer Res 65: 8583-8586.
2. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444.
3. Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217.
4. Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454: 428-435.
5. Roncucci L, Mora E, Mariani F, Bursi S, Pezzi A, et al. (2008) Myeloperoxidase- positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 17: 2291-2297.
6. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, et al. (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. Jama 282: 1254-1257.
7. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, et al. (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146: 376-389.
8. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, et al. (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57: 2909-2915.
9. Carothers AM, Moran AE, Cho NL, Redston M, Bertagnolli MM (2006) Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Res 66: 6432-6438.
10. Nathan C (2002) Points of control in inflammation. Nature 420: 846-852.
11. Gilroy DW, Colville-Nash PR, McMaster S, Sawatzky DA, Willoughby DA, et al. (2003) Inducible cyclooxygenase-derived 15-deoxy(Delta)12-14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. Faseb J 17: 2269-2271.
12. Rajakariar R, Hilliard M, Lawrence T, Trivedi S, Colville-Nash P, et al. (2007) Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci USA 104: 20979-20984.
13. Serhan CN, Chiang N, Van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361.
14. itzpatrick FA, Wynalda MA (1983) Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro. J Biol Chem 258: 11713-11718.
15. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, et al. (2001) Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 22: 199-204.
16. Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M, et al. (2002) 15- deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. J Biol Chem 277: 10459-10466.
17. Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6: 1191-1197.
18. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4- hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128.
19. West JD, Marnett LJ (2006) Endogenous reactive intermediates as modulators of cell signaling and cell death. Chem Res Toxicol 19: 173-194.
20. Grimsrud PA, Xie H, Griffin TJ, Bernlohr DA (2008) Oxidative stress and covalent modification of protein with bioactive aldehydes. J Biol Chem 283: 21837-21841.
21. Anderson MM, Hazen SL, Hsu FF, Heinecke JW (1997) Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta- unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 99: 424-432.
22. Uchida K, Kanematsu M, Morimitsu Y, Osawa T, Noguchi N, et al. (1998) Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J Biol Chem 273: 16058-16066.
23. Esterbauer H, Eckl P, Ortner A (1990) Possible mutagens derived from lipids and lipid precursors. Mutat Res 238: 223-233.
24. Chen Y, Morrow JD, Roberts LJ, 2nd(1999) Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J Biol Chem 274: 10863-10868.
25. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, et al. (2000) Anti- inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403: 103-108.
26. Di Cristofano A, Pandolfi PP (2000) The multiple roles of PTEN in tumor suppression. Cell 100: 387-390.
27. Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
28. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, et al. (2002) Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 277: 20336-20342.
29. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, et al. (2003) Redox regulation of PI 3-kinase signalling via inactivation of PTEN. Embo J 22: 5501-5510.
30. Moos PJ, Edes K, Cassidy P, Massuda E, Fitzpatrick FA (2003) Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem 278: 745-750.
31. Gayarre J, Stamatakis K, Renedo M, Perez-Sala D (2005) Differential selectivity of protein modification by the cyclopentenone prostaglandins PGA1 and 15- deoxy-Delta12,14-PGJ2: role of glutathione. FEBS Lett 579: 5803-5808.
32. Landar A, Shiva S, Levonen AL, Oh JY, Zaragoza C, et al. (2006) Induction of the permeability transition and cytochrome c release by 15-deoxy-Delta12,14- prostaglandin J2 in mitochondria. Biochem J 394: 185-195.
33. Downward J (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10: 262-267.
34. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245.
35. Plas DR, Thompson CB (2005) Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24: 7435-7442.
36. Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trispho- sphate. J Biol Chem 273: 13375-13378.
37. Shahabi NA, Chegini N, Wittliff JL (1987) Alterations of MCF-7 human breast cancer cell after prostaglandins PGA1 and PGF2 alpha treatment. Exp Cell Biol 55: 18-27.
38. Chinery R, Coffey RJ, Graves-Deal R, Kirkland SC, Sanchez SC, et al. (1999) Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res 59: 2739-2746.
39. Narumiya S, Fukushima M (1986) Site and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopen- tenone prostaglandins, a reaction leading to growth inhibition. J Pharmacol Exp Ther 239: 500-505.
40. van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H (2002) Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem 277: 17901-17905.
41. Coombs GS, Covey TM, Virshup DM (2008) Wnt signaling in development, disease and translational medicine. Curr Drug Targets 9: 513-531.
42. Huang W, Chang HY, Fei T, Wu H, Chen YG (2007) GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene 26: 2471-2482.
43. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S (2001) Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/ lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 153: 1161-1174.
44. Hays E, Schmidt J, Chandar N (2009) Beta-catenin is not activated by downregulation of PTEN in osteoblasts. In Vitro Cell Dev Biol Anim 45: 361-370.
45. Shin SY, Chin BR, Lee YH, Kim JH (2006) Involvement of glycogen synthase kinase-3beta in hydrogen peroxide-induced suppression of Tcf/Lef-dependent transcriptional activity. Cell Signal 18: 601-607.
46. McCulloch MW, Coombs GS, Banerjee N, Bugni TS, Cannon KM, et al. (2009) Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives. Bioorg Med Chem 17: 2189-2198.
47. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta- catenin signaling axis. Science 310: 1504-1510.
48. Yin Y, Shen WH (2008) PTEN: a new guardian of the genome. Oncogene 27: 5443-5453.
49. Gericke A, Munson M, Ross AH (2006) Regulation of the PTEN phosphatase. Gene 374: 1-9.
50. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, et al. (2006) PCAF modulates PTEN activity. J Biol Chem 281: 26562-26568.
51. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, et al. (2004) Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci USA 101: 16419-16424.
52. Connor KM, Subbaram S, Regan KJ, Nelson KK, Mazurkiewicz JE, et al. (2005) Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation. J Biol Chem 280: 16916-16924.
53. Covey TM, Edes K, Fitzpatrick FA (2007) Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene 26: 5784-5792.
54. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408: 239-247.
55. Wagner TM, Mullally JE, Fitzpatrick FA (2006) Reactive lipid species from cyclooxygenase-2 inactivate tumor suppressor LKB1/STK11: cyclopentenone prostaglandins and 4-hydroxy-2-nonenal covalently modify and inhibit the AMP-kinase kinase that modulates cellular energy homeostasis and protein translation. J Biol Chem 281: 2598-2604.
56. Cernuda-Morollon E, Pineda-Molina E, Canada FJ, Perez-Sala D (2001) 15- Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J Biol Chem 276: 35530-35536.
57. Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, et al. (2002) Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 277: 46116-46122.
58. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659.
59. Xu Q, Wang Y, Dabdoub A, Smallwood PM, Williams J, et al. (2004) Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell 116: 883-895.